Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), it helps pharmaceutical, biotechnology, and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing assistance. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its capital and commercial divisions assist with project funding and sales and marketing efforts.
Quintiles Transnational provides consulting on product development and commercialization services for drugs that are ready to go to market. Services include conducting late phase clinical trials on drugs after they've been released (post-marketing research) and setting up the information technology a drug maker needs to support a marketed drug. Additionally, the company provides financing and partnering support which invests in client companies (either through cash or services) in return for royalties on sales of approved products.
The company has operations in about 60 countries. In recent years Quintiles Transnational has been focusing on international expansion, especially in Asia. In 2011 it launched new businesses in China, India, Indonesia, Korea, and South Africa.
Demand for outsourced clinical development services has been growing as belt-tightening pharma and biotech companies look to trim costs even as they are desperate to find and develop new products. Quintiles Transnational has focused efforts on developing services that help its clients reduce risk and time-to-market. For instance its Cenduit subsidiary, a joint venture with Thermo Fisher Scientific, helps control clinical trials costs by automating delivery of supplies, among other things.
In 2011 the company launched its Infosario online subscription cloud service for managing clinical trial data. Such data and data management is the company's meat and potatoes and to fill out its plate, it also acquired Cambridge Massachusetts-based Outcome Sciences in 2011. Outcome provides patient registry, web-based data collection, and post trial product performance data for patients, pharmaceutical manufacturers, providers and government agencies.
Quintiles branched out into genomic testing services in 2012 when it acquired Expression Analysis for an undisclosed price. The purchase meets Qunitiles goal of helping customers develop diagnostic tools and personalized medicines based on a specific patient's genetic makeup, a growing trend in the pharmaceuticals industry.
To assist in broadening its international reach in Asia and Europe, in recent years Quintiles opened or expanded facilities in China, Singapore, Scotland, and Spain. In 2011 it opened a new office in the UK to serve as the headquarters of its EU operations, and in 2012 it established a commercial solutions office in Brazil to expand in Latin America. The commercial division also formed a joint venture with Dayarn Pharma, a firm based in the United Arab Emirates, to expand in the Middle East and North Africa.
Because Quintiles' customers and alliance partners tend to be larger firms (such as Eli Lilly and AstraZeneca), it has not been pinched as hard by the softened credit market. Smaller biotech firms, which have had a hard time attracting fresh capital to continue their research, account for only a fraction of the company's revenues.
The company has exited most of its preclinical services businesses, which provided services like toxicology testing and chemistry services, to focus on its core clinical (i.e., human testing) operations.